Drug intelligence / Profile preview

AN0444

Development stage: Preclinical
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules
Administration: Suprachoroidal (ophthalmic Injection)

Overview

AN0444 is a small molecule therapeutic candidate being developed by Beijing Anlong Biomedical for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). As of early 2024, the program is in the IND-enabling phase of development. While the specific biological target and mechanism of action have not been publicly disclosed by the developer, the drug is a key asset in Anlong's pipeline focusing on metabolic and chronic liver diseases.

Beyond the preview

Go deeper on AN0444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN0444.

Explore the full profile